Chris Cardon, graduated as a Master in Pharmaceutical Sciences from Ghent University in 1993, and MBA Vlerick Ghent Management School in 1995. He founded Mooss Pharma in 1996, a company which developed human OTC products, divested to Perrigo (Omega Pharma) in 2001. Hereafter, Chris Cardon started a new venture in 2002 with Ecuphar, to capitalise on opportunities in the animal health industry. When Ecuphar was acquired (reverse takeover) by Animalcare Group Plc in 2017 (ANCR-LSE), Chris Cardon became C.E.O. of Animalcare Group Plc. Oct 2018, Chris Cardon stepped down, remaining a board member of Animal Group Plc. In 2019, he took on a new venture project namely Ziphius. This company is leveraging on own developed self-amplifying RNA and LNP technology to develop vaccines & therapeutics.